I've gone looking for the information on long term usage of ivermectin and hcq and can't find any clinical data regarding Covid-19.
I also have to dispute the concept of a media blackout on these treatments given the easily found releases on Britain's new PRINCIPLE testing that includes ivermectin as a tested treatment for COVID-19. When I do find sites toutingb the effectiveness of these two treatments, they are generally hyper-partisan and rely on anecdotal data rather than reproducible testing.
Then please explain why Biden voting liberals on youtube who talk about Ivermectin get demonitized. Any time Brett Weinstein talks about Ivermectin as a treatment to COVID, the video gets demonitized and gets a strike from youtube.
No data available to suggest a link between India’s reduction of COVID-19 cases and the use of ivermectin
"In summary, neither the epidemiological nor the clinical data support the claim that the reduction in COVID-19 cases in India is due to the use of ivermectin. Media outlets making that claim based this solely on temporal correlation without providing evidence of a causal relationship. Contradicting this claim, epidemiological data show that contagiousness began to decrease in India before the release of new official guidelines recommending the use of ivermectin."
You also have to take into account the need for ivermectin to be dosage-tuned to each patient based on weight, and that serious contraindications exist for patients with any type of liver issues or on anticoagulants.
A large body of research exists demonstrating hydroxy chloroquine's lack of efficacy as a prophylaxis for COVID-19.
The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials - PubMed
"Background: Populations such as healthcare workers (HCW) that are unable to practice physical distancing are at high risk of acquiring Coronavirus disease-2019 (COVID-19). In these cases pharmacological prophylaxis would be a solution to reduce severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) transmission. Hydroxychloroquine has in vitro antiviral properties against SARS CoV-2. We therefore sought to determine the efficacy and safety of hydroxychloroquine as prophylaxis for COVID-19.
Methods and findings: We electronically searched EMBASE, MEDLINE, the Cochrane COVID-19 Register of Controlled Trials, Epistemonikos COVID-19, clinicaltrials.gov, and the World Health Organization International Clinical Trials Registry Platform up to September 28th, 2020 for randomized controlled trials (RCTs). We calculated pooled relative risks (RRs) for dichotomous outcomes with the corresponding 95% confidence intervals (CIs) using a random-effect model. We identified four RCTs (n = 4921) that met our eligibility criteria. The use of hydroxychloroquine, compared to placebo, did not reduce the risks of developing COVID-19 (RR 0.82, 95% CI 0.65 to 1.04, moderate certainty), hospitalization (RR 0.72, 95% CI 0.34 to 1.50, moderate certainty), or mortality (RR 3.26, 95% CI 0.13 to 79.74, low certainty), however, hydroxychloroquine use increased the risk of adverse events (RR 2.76, 95% CI 1.38 to 5.55, moderate certainty).
Conclusion: Although pharmacologic prophylaxis is an attractive preventive strategy against COVID-19, the current body of evidence failed to show clinical benefit for prophylactic hydroxychloroquine and showed a higher risk of adverse events when compared to placebo or no prophylaxis.
Conflict of interest statement
The authors have declared that no competing interests exist."